SCHEMBL26033461

SCHEMBL26033461

ICc1ccc(C2CCNCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
HTR2C P28335 8/20 0.52
QDPR P09417 1/20 0.47
HTR3A P46098 1/20 0.44
KDM1A O60341 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
ESRRB O95718 2/20 0.40
ESR1 P03372 2/20 0.40
ESRRG P62508 2/20 0.40
KCNH2 Q12809 1/20 0.39
NAMPT P43490 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16527200 0.81 HDAC1 (0.41) HTR2CESR1KCNH2HTR2B
SCHEMBL8284802 0.80 SLC18A3 (0.55) SLC18A3SIGMAR1HTR2CQDPRHTR3A
Enefexine SCHEMBL499360 0.80 SLC18A3 (0.55) SLC18A3SIGMAR1HTR2CQDPRHTR3A
SCHEMBL27489026 0.80 SLC18A3 (0.55) SLC18A3SIGMAR1HTR2CQDPRHTR3A
SCHEMBL11267221 0.79 HAO1 (0.42) HTR2CKCNH2HTR2B
Enefexine SCHEMBL4886231 0.78 SLC18A3 (0.53) SLC18A3SIGMAR1HTR2CQDPRHTR3A
SCHEMBL22567480 0.78 HTR2C (0.57) SLC18A3SIGMAR1HTR2CQDPR
SCHEMBL14282659 0.77 SLC18A3 (0.68) SLC18A3SIGMAR1HTR2CQDPRESRRB
SCHEMBL7917964 0.77 SLC18A3 (0.52) SLC18A3SIGMAR1HTR2CQDPR
SCHEMBL6749137 0.77 SLC18A3 (0.52) SLC18A3SIGMAR1HTR2CQDPRHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023158221-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS 주식회사 카나프테라퓨틱스 2023-08-24 WO disclosed